The expression of cGAS in PBMCs showed a dose response to type I IFN stimulation in vitro, consistent with it being an ISG. Targeted measurement of cGAMP by tandem mass spectrometry detected cGAMP in 15% of the SLE patients (7 of 48) but none of the normal (0 of 19) or rheumatoid arthritis (0 of 22) controls. Disease activity was higher in SLE patients with cGAMP versus those without cGAMP.
Conclusion. Increased cGAS expression and cGAMP in a proportion of SLE patients indicates that the cGAS pathway should be considered as a contributor to type I IFN production. Whereas higher cGAS expression may be a consequence of exposure to type I IFN, detection of cGAMP in patients with increased disease activity indicates potential involvement of this pathway in disease expression.
The type I interferons (IFNs) are strongly implicated in the pathogenesis of systemic lupus erythematosus (SLE) (1) , based on the following key findings: 1) twothirds of SLE patients have a blood IFN signature, 2) gene variants that enhance type I IFN production are increased in SLE, 3) therapeutic administration of type I IFN for virus infection or cancer induces SLE in a small percentage of patients, and 4) preliminary findings indicate that type I IFN receptor blockade with a biologic agent leads to improvement in the clinical parameters of SLE (2) . How, where, and when type I IFN is initially stimulated in lupus patients is uncertain. In vitro studies, including those of our own group (3), have shown that IFNa is induced by immune complexes containing (ribo)nucleoprotein antigens (4, 5) . However, Niewold et al (6) have shown that serum from a significant proportion of SLE family members without autoantibodies induce IFN-stimulated genes (ISGs) in responder cells. Data from clinical trials using biologic agents targeting IFNa led Petri and colleagues (7) to suggest that other IFNs may well be involved. Microarray analysis of skin from SLE (and dermatomyositis) patients revealed that the ISG signature was correlated with IFNb and IFNg, but not IFNa (8) . Finally, Chiche et al (9) reported that complex IFN signatures in SLE are not restricted to the IFNa signature but might also involve IFNb and IFNg. These findings strongly suggest that other interferon pathways are activated, especially prior to the production of high-affinity IgG autoantibodies.
Type I IFNs include 13 IFNa proteins, 1 IFNb protein, and several less-explored members, including IFNe, IFNk, IFNt, and IFNv. IFNb can be produced by almost any cell following stimulation by (viral) nucleic acids. Release of this cytokine serves to prime or amplify type I IFN by other cells, especially plasmacytoid dendritic cells that are the main producers of IFNa. It has been shown that in monogenetic disorders associated with aberrant production of type I IFN and SLE-like features ("interferonopathies"), responsible mutations activate pathways that induce IFNb rather than IFNa (10, 11) . This observation is consistent with the idea that elevated levels of type I IFN other than IFNa can contribute to the pathogenesis of SLE. Similar observations have been made in mouse models, including a mouse model of lupus (12, 13) .
Cytosolic nucleic acid sensors play a crucial role in the detection of pathogens that have breached membrane barriers (14) . Among the most important cytosolic DNA sensors recently identified is cyclic GMP-AMP synthase (cGAS) (15, 16) . Binding of double-stranded DNA to cGAS causes a conformational change in the active site of cGAS, which uses ATP and GTP to synthesize the cyclic dinucleotide cGAMP (16, 17) . Cyclic GAMP then functions as an endogenous second messenger, binding directly to the adapter protein, stimulator of IFN genes (STING), culminating in the activation of the transcription factor, IFN regulatory factor 3 (IRF-3) and synthesis of IFNb (18) .
Given the central role played by type I IFN in the pathogenesis of SLE, we examined cGAS expression and cGAMP production in patients with SLE. Whereas increased cGAS expression could be secondary to exposure to type I IFN, detection of cGAMP in a subset of SLE patients, especially those with high scores on the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), suggests that the cGAS pathway is activated and may contribute to disease in some SLE patients.
PATIENTS AND METHODS
Patient population. Patients who fulfilled the American College of Rheumatology (ACR) criteria for SLE (19) and gave their informed consent to participate were included in this study. Samples were collected in compliance with the Declaration of Helsinki. Ethical approval was granted by the University of Washington (approval no. 39712).
Information about the patient's medical history, number of classification criteria fulfilled, laboratory findings, and damage accrual data was obtained and measured using the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) (20) . Whole blood samples were collected and disease activity was measured with the SELENA-SLEDAI (21) at the time of the clinic visit. The SELENA-SLEDAI, which measures disease activity (range 0-105) during the preceding 10 days, includes 24 clinical and laboratory variables and is weighted by organ system. Damage accrual was evaluated using the SDI, which assigns a numerical value to organ damage regardless of attribution (20) . Patients with rheumatoid arthritis (RA) according to the ACR criteria (22) were used as an inflammatory disease control population.
Three cohorts of SLE patients were studied: an initial cGAS test cohort (cohort 1), in which stored complementary DNA (cDNA) samples that had been obtained from 51 SLE patients and 20 normal controls were tested for cGAS expression by quantitative PCR (qPCR); an initial cGAMP test cohort (cohort 2), in which peripheral blood mononuclear cells (PBMCs) derived from fresh blood samples obtained from 17 SLE patients, 10 RA patients, and 9 normal controls were tested for cGAMP by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS); and a third test cohort (cohort 3), in which cGAS and cGAMP were examined in the same group of 48 SLE patients, 22 RA patients, and 19 normal controls. Some cohort 2 patients were included in cohort 3, depending solely on the availability of at least 25 million cells for study.
Real-time qPCR for cGAS and ISGs. Total RNA was isolated from PBMC using an RNeasy Mini kit with a DNase treatment step (Qiagen). We generated cDNA using 100 ng of RNA with a high-capacity cDNA reverse transcription kit and random primers (Applied Biosystems). Reactions were performed in duplicate on an ABI StepOne Plus instrument using the following primers: for cGAS, 5
0 -GAAGAAACATG-GCGGCTATC-3 0 (forward) and 5 0 -TGAGGGTTCTGGGTA-CATACG-3 0 (reverse); and for 18S, 5 0 -GAGGGAGCCTG-AGAAACGG-3 0 (forward) and 5 0 -GTCGGGAGTGGGTAA-TTTGC-3 0 (reverse). A 2-stage cycle of 958C for 15 seconds and 608C for 1 minute was repeated for 40 cycles, followed by a dissociation stage.
The IFN score was calculated from the combined expression of 3 ISGs (Mx-1, CXCL10, and protein kinase R [PKR]) as described elsewhere (23) . Threshold cycle values were set as a constant threshold of 0.2, and fold changes in gene expression were then calculated using the 2 -DDCt method. Purification and detection of cGAMP. PBMCs were lysed with 1 ml of 80% methanol spiked with 5 nM heavy isotope-labeled cGAMP (cGAMP*) containing 13 C, 15 N-labeled AMP as internal standard. Cell extracts were sonicated on ice for 1 minute with settings of 20% duty cycle and 1 output. Cell debris was pelleted at 14,000 revolutions per minute for 10 minutes. Methanol extraction solution was transferred to a new tube and evaporated using a SpeedVac. The cGAMP was further purified with a solid-phase extraction column (Oasis WAX column; Waters) and resuspended in 50 ml of Optima LC-MS water (Thermo Scientific) for mass spectrometry. For targeted detection of cGAMP, a multiple reaction-monitoring assay was developed, using a Waters Xevo TQS mass spectrometer coupled with cGAS IN SLEan ultra-performance liquid chromatograph. In the assay, 2 transitions of each target ion were monitored: for cGAMP, 1675.1/ 152.1 (parent ion/daughter ion) and 1675.1/136.0; for cGAMP*, 1690.0/152.1 and 1690.0/146.0.
Sequencing of 3 0 repair exonuclease 1 (TREX1). Mutation screening of TREX1 was performed by PCR amplification of genomic DNA segments (sequences available upon request from the corresponding author) and direct sequencing of the products using BigDye terminator chemistry and a 3130 DNA sequencer (Applied Biosystems) as described previously (24) . The mutation description is based on the reference cDNA sequence for TREX1 (NM_033629).
Statistical analysis. Categorical variables were compared using Fisher's exact test. Mean data were compared using a t-test or Wilcoxon's rank sum test for normally distributed or non-normally distributed data, respectively. Correlations were performed using linear regression. P values less than 0.05 were considered statistically significant.
RESULTS
Increased cGAS expression in a proportion of SLE patients and responsiveness to type I IFN. To determine levels of cGAS expression in SLE patients, we quantified the expression of messenger RNA for cGAS by qPCR using cDNA derived from sequential blood samples collected from patients at the University of Washington Clinic (cohort 1). In these 51 SLE patients and 20 normal controls, cGAS expression was significantly higher in the SLE patients (mean 6 SD relative expression of cGAS 1.17 6 0.62 versus 0.77 6 0.31 in healthy controls; P 5 0.004) ( Figure 1A ). Almost half of the SLE population (46.9%) had cGAS expression .1 SD above the mean value in healthy controls, with 26.5% having values .2 SD Although cGAS does not feature as a highly induced ISG in SLE (9) , there is at least 1 report that cGAS is an ISG (25) . To determine whether the increase in cGAS expression could be explained as a secondary consequence of type I IFN production, we analyzed the correlation between the cGAS level and the IFN score, a composite score derived from the expression of 3 ISGs (Mx-1, CXCL10, and PKR). Expression of cGAS and the IFN score were significantly correlated ( Figure 1B) .
To clearly determine whether, in fact, cGAS expression could be influenced by exposure to type I IFN, we exposed PBMCs isolated from normal controls to increasing concentrations of IFNa. Following exposure to IFNa, cGAS expression increased in a dose-responsive manner ( Figure 1C ), similar to the ISG CXCL10 ( Figure  1D ). Of interest, whereas a marked increase in cGAS expression was observed in PBMCs from some healthy individuals following incubation with type I IFN, PBMCs from other normal controls responded in a more limited manner, indicating considerable individual variation (Figures 1E and F) . Overall, these findings suggests that, in SLE patients, cGAS could be elevated as a consequence of exposure to type I IFN and/or that expression of cGAS may be induced by an unknown DNA stimulus, which then primes for enhanced type I IFN responses in a positive feedback cycle.
Cytosolic DNA binding to cGAS induces a conformational change and dimerization of cGAS, leading to synthesis of the cyclic dinucleotide cGAMP (16, 17) . To determine whether type I IFN-induced expression of cGAS (without activation by DNA) was capable of inducing the expression of cGAMP, we stimulated PBMCs from 4 healthy donors with IFNa and examined cGAMP production by mass spectrometry. We could not detect cGAMP in type I IFN-stimulated PBMCs from these 4 ) from SLE patients (n 5 48), rheumatoid arthritis (RA) patients (n 5 22), or healthy controls (n 5 19) were isolated as described in A, and the presence of cGAMP was measured by mass spectrometry using multiple reaction monitoring. Heavy isotope-labeled cGAMP was spiked into each sample as an internal standard, and the mass spectrum of an internal standard (arrow) was used to determine the peak of the endogenous cGAMP. Representative results for individual SLE patients, RA patients, and a normal control are shown. The x-axis shows the retention time of the parent/daughter ions: for cGAMP, 1675.1/136.0, and for the internal standard heavy isotope-labeled cGAMP, 1690.0/146.0. The y-axis shows the relative intensity of the cGAMP mass spectrum signal. Detection of cGAMP in SLE PBMCs. Since increased cGAS expression was insufficient to induce cGAMP, we sought to determine whether cGAS was enzymatically active in SLE patients and, by inference, stimulated by ligand. We used mass spectrometry to detect the cyclic dinucleotide cGAMP in PBMCs from 2 additional cohorts of SLE patients (cohorts 2 and 3). The cGAMP was extracted from PBMCs, and the cyclic dinucleotide was identified by mass spectrometry using multiple reaction monitoring, with heavy isotope-labeled cGAMP as internal standard. In the initial optimization of the methodology, we detected cGAMP in DNA-transfected ( Figure  2A ), as well as herpes simplex virus-infected (data not shown), THP-1 cells, as has been reported by other investigators (15) . When PBMCs from cohort 3 subjects (48 SLE patients, 22 RA patients, and 19 normal controls) were tested by the same methods, we detected cGAMP in 7 of 48 SLE patients (15%) but in none of the samples from the RA patients or normal controls ( Figure 2B ). Samples from 5 of these 7 SLE patients were available for DNA sequence analysis. No TREX-1 mutations were detected in these 5 patients.
Higher SLEDAI scores in patients with detectable cGAMP. To determine what clinical characteristics might distinguish patients with detectable cGAMP, we examined clinical, serologic, and treatment variables in SLE patients with and without cGAMP ( Table 1) . We first examined the duration of disease, as we postulated that activation of the cGAS pathway may be an early abnormality that primes cells such as plasmacytoid dendritic cells for IFNa responses. However, we observed no differences in disease duration between the cGAMP1 and cGAMP-patients (mean 10.57 years versus 12.58 years; P 5 0.623).
We have shown that antimalarial drugs can attenuate cGAS activation (26) . To determine whether drug therapy could explain suppression of cGAMP, we compared the use of hydroxychloroquine, corticosteroids, and other therapies. A similar proportion of cGAMP1 and cGAMP-patients were prescribed hydroxychloroquine (100% versus 80%; P 5 0.32) and prednisone (57% versus 53%; P 5 1.00), with comparable dosing regimens of mycophenolate mofetil (28% versus 26%; P 5 0.78). A numerically higher proportion of cGAMP1 patients had a history of cyclophosphamide exposure, but this did not reach statistical significance.
We also explored disease severity by examining values on the SLEDAI and SDI in each patient. Disease activity was significantly higher in cGAMP1 patients as compared to cGAMP-patients (mean 6 SD SLEDAI 7.00 6 5.09 versus 3.52 6 2.78, respectively; P 5 0.0102). Damage, as measured by the SDI, was similar in the 2 groups (mean 6 SD 0.71 6 1.49 versus 0.95 6 1.14; P 5 0.624). With regard to specific organ involvement, there were no statistically significant differences between the frequency of active renal, neurologic, or articular disease between cGAMP1 and cGAMP-patients. Two cGAMP1 patients (29%), but no cGAMP-patients, had active cutaneous disease at the time of testing. No distinguishing serologic abnormalities were demonstrated in cGAMP1 versus cGAMP-patients. The groups were comparable in terms of age and ethnicity. There were no overt infections in the cGAMP1 population. A higher proportion of men expressed cGAMP, but with only 4 men in this sample, the difference was not statistically significant. 
DISCUSSION
Aberrant IFN production has long been implicated in the pathogenesis and disease activity of SLE. As discussed above, recent results indicate that the IFN signature observed in PBMCs from SLE patients may not solely be a response to IFNa, which suggests that other type I IFNs as well as type II IFNs may play a role as immune adjuvants in SLE and related systemic autoimmune disorders. Although cGAS appears to be a prominent, if not the dominant, cytosolic DNA sensor responsible for inducing IFNb in response to infections by a variety of pathogens (18) , its role in human autoimmune diseases has not been studied in any detail. This study is the first to show evidence of cGAS/cGAMP activation in human SLE. We found a modest increase in cGAS transcripts in almost half of the SLE patients (46.9%) as compared to the healthy controls. We demonstrated that while such an increase could be explained by a response to type I IFN, since cGAS is a weakly induced ISG, we could also detect the product of cGAS enzymatic activity, cGAMP, in ;15% of SLE patients, indicating ligand activation of cGAS in a subset of patients.
While there was a significant correlation between cGAS expression and the type I IFN score in PBMCs from patients with SLE, suggesting a cause-and-effect relationship, it was of interest that even in the normal control population, there was considerable variation in the expression of cGAS transcript in response to IFNa. This was not simply explained by the rate of response, as the differential response was seen at both 4 and 24 hours. It remains to be determined whether such variation is due to regulation of cGAS itself or is due to variation in IFNa receptor and downstream signal transduction pathways. This would be particularly interesting to explore in SLE patients in whom genetic variants in tyrosine kinase 2 and IRF-5 have been observed (27) . We also noted that, on average, cGAS expression was lower in RA PBMCs compared to SLE PBMCs. Whether this reflects the often-contrasting cytokine profiles in these diseases (28) or drug therapy remains to be determined.
An important question is why cGAMP was detected in only 15% of patients with SLE. The large numbers of cells required and the relatively small cGAMP signal observed in a few patients could be explained by the fact that cGAMP is rapidly destroyed by phosphodiesterases, so that detection may require generation of very high levels of cGAMP. Consistent with this hypothesis, patients with detectable cGAMP had significantly higher SLEDAI scores. In this scenario, cGAS/cGAMP stimulation of IFNb and other proinflammatory cytokines generated by activation of IRF-3 and NF-kB (18) may be a contributory cause of inflammation and disease activity.
Since IFNb primes cells to enhance IFNa production (29), we investigated whether cGAMP may be more readily detected in patients with recent-onset SLE prior to the multiple downstream effects caused by IgG-containing immune complexes that contain nucleoprotein antigens that activate plasmacytoid dendritic cells and neutrophils, as well as other immune cells (30, 31) . However, we observed that this was not the case and that there was no association between cGAMP detection and disease duration.
Patients with SLE have changes in the relative proportions of cells in PBMCs. We therefore cannot exclude the possibility that some of the findings observed in this study are due to alterations in cell proportions. However, since cGAMP was not detected in any of the normal or RA disease controls and was only detected in 7 of a total of 48 SLE patients tested indicates that it is unlikely that this biologically meaningful signal is explained by alterations in cell subsets. Nevertheless, it will be of considerable interest to determine which cell type(s) synthesizes cGAMP, as this may provide a clue to its genesis.
Another key question is what activates cGAS to produce cGAMP in the subset of cGAMP1 SLE patients. Among the many possibilities that could explain this association are chronic infection with DNA viruses that have long been implicated in SLE (32), endogenous retrovirus DNAs that have been proposed to activate cGAS in mice (33) , or oxidized mitochondrial DNA that stimulates inflammatory cytokines in a STING-dependent manner (31) . We cannot, however, exclude the possibility that cGAMP generation is a consequence of the uptake of nucleoprotein from tissue damage and is therefore a consequence, rather than a cause, of inflammation. It is relevant to note that even when DNA from dying cells is taken into endosomal compartments, DNA can enter the cytosol and activate cGAS/ cGAMP, as in DNase II deficiency (13) .
While almost nothing is known about cGAMP expression in human autoimmune disorders, there is clear evidence that the cGAS/STING pathway is implicated in diseases with features of lupus in murine models. Deficiency of the 3 0 -5 0 DNA exonuclease TREX-1 in mice leads to an autoimmune myocarditis and a mild lupus-like systemic autoimmunity (34) . Disease is markedly attenuated in TREX-1-knockout mice that lack the type I IFN receptor, as well as when the mice are rendered deficient in STING (34) . Furthermore, TREX-1-knockout mice that are deficient in cGAS are fully protected from disease (12, 13) . In a second mouse model where DNase II deficiency leads to profound inflammation and autoimmunity, deficiency of cGAS protected the mice from disease (13) . It is relevant to point out that 1-2% of SLE patients have mutations in TREX-1 that are thought to contribute to the lupus-like syndrome (35, 36) . However, we did not detect TREX-1 mutations in 5 of the 7 patients from whom DNA was available.
We have demonstrated increased SLE disease activity in a small subset of SLE patients who have activation of the cGAS/cGAMP pathway. These results will need to be examined in larger numbers of patients in whom cGAS, cGAMP, IFNb, ISGs, and other cytokines are prospectively evaluated. We recently reported that in addition to the inhibition of Toll-like receptor (TLR) stimulation, antimalarial drugs such as hydroxychloroquine and quinacrine attenuated cGAS production of cGAMP and IFNb (26) . Although this effect remains to be shown in vivo, our results lend support to the theory that antimalarial drugs provide therapeutic benefit not only by attenuating TLR activation (37) , but also by interfering with the cGAS/STING pathway in some patients with SLE.
